| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1096 | Bos-318 | Novel. highly potent, selective, cell-permeable furin inhibitor, rescuing key features of cystic fibrosis airway disease |
|
| DCC1097 | Bos-6-2-2-6-crbn | Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL |
|
| DCC1098 | Bot-64 | Novel IKK-2 inhibitor, targeting the Ser177 and/or Ser181 residues in the kinase's activation loop domain. |
|
| DCC1099 | Bp1.4160 | Novel and highly potent histamine H3 receptor ligand |
|
| DCC1100 | Bp-1-108 | Potent and selective STAT5 inhibitor |
|
| DCC1101 | Bp13944 | Novel, Potential Dengue Virus NS2B/NS3 Protease Inhibitor |
|
| DCC1102 | Bp2-94 | Histamine H3 receptor agonist prodrug |
|
| DCC1103 | Bpc Hydroiodide | Novel modulator of TTD-PHD histone reader module, binding to the TTD groove, competing with linker binding and promoting open TTD-PHD conformations |
|
| DCC1104 | Bph-1218 | Novel potent SQS inhibitor |
|
| DCC1105 | Bph-651 | Novel CrtM inhibitor |
|
| DCC1106 | Bph-652 Potassium | Squalene synthase (SQS) inhibitor, potently inhibiting CrtM |
|
| DCC1107 | bpmetap1-in-15 | The first potent inhibitor of Burkholderia pseudomallei methionine aminopeptidase |
|
| DCC1108 | Bpn-14136 Featured | Novel RBP4 antagonist with good in vitro potency and selectivity and optimal rodent pharmacokinetic (PK) and pharmacodynamic (PD) characteristics |
|
| DCC1109 | Bpr1k871 | Novel potent and selective dual FLT3/AURKA inhibitor |
|
| DCC1110 | Bpv(phen) | Potent direct PTEN inhibitor |
|
| DCC1111 | Bpv(pic)k2 | Potent and se;rctive PTEN inhibitor, activating the insulin receptor kinase, inhibiting the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors of rat liver endosomes |
|
| DCC1112 | Bpyo-34 | Novel apoptosis signal-regulating kinase 1 (ASK1) inhibitor with IC50 of 0.52μM in vitro in kinase assay |
|
| DCC1113 | bractelactone | Novel potent inhibitor of human neutrophil activations |
|
| DCC1114 | BRAF PROTAC P4B | Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $292.50 Total: $29,250.00 50 $338.00 Total: $16,900.00 25 $396.50 Total: $9,912.50 10 $468.00 Total: $4,680.00 5 $552.50 Total: $2,762.50 |
|
| DCC1115 | Brasofensine Maleate | Monoamine Reuptake Inhibitor |
|
| DCC1116 | Brassilexin | Inhibitor of cyclobrassinin hydrolase, a unique enzyme from the fungal pathogen Alternaria brassicicola |
|
| DCC1117 | Brazilein | Natural small molecule isolated from dried heartwood of Caesalpinia sappan L, exhibiting multi-pharmacological activities |
|
| DCC1118 | Brd0026 | Novel multistage antimalarial inhibitor |
|
| DCC1119 | Brd0761 | Novel Inhibitor of Clostridium difficile |
|
| DCC1120 | Brd20322 | Novel potent inhibitor of spCas9, disrupting spCas9-DNA binding and exerting dose and temporal control of spCas9 in human cell lines |
|
| DCC1121 | Brd2577 | Novel HDAC inhibitor, inhibiting multiple HDAC enzymes and modulates acetylation levels in cells |
|
| DCC1122 | brd2761 | Positive control for HSPC toxicity; Inhibitor of STK33 |
|
| DCC1123 | Brd3067 | Negative control for tubastatin A |
|
| DCC1124 | Brd3316 | Novel inhibitor of parasite phenylalanyl-tRNA synthetase (PheRS) |
|
| DCC1125 | Brd3811 | Novel non-histone nuclear substrate of histone deacetylase 8 (HDAC8) |
|
